News and Announcements
A Typical LP Composition In A Venture Fund
- Published December 14, 2022 8:39AM UTC
- Publisher Osama Hassan
- Categories Capital Raising Tips
Do you know what the hardest part of a VC’s journey is?
It’s raising capital for the venture fund itself.
Founders – take note – you’re not the only ones out there raising capital …
Let’s continue our journey of understanding the inner workings of VCs …
VCs depend on limited partners (LPs) for capital.
Welcome to the world of LPs!
In this universe, you’ll find a range of institutional investors like:
Foundations,
University Grants,
Super/Pension Funds,
Fund of Funds,
Family Offices, and
Sovereign Wealth Funds
Each one has different sources of capital, investment criteria, constraints and return expectations.
Just as smart founders choose the right VCs and investors on their cap table, the best fund managers pick LPs that matter, can add value and shape their journey.
The best ones build rich, collaborative, two-way networks.
To achieve their target returns LPs – institutional investors – have to constantly juggle with different types of assets of which VC is one kind.
Let’s talk about asset classes in another post …
For now, here’s a chart that outlines the typical mix of LPs in a venture fund.
✌️
Click here to view the original Linkedin post.
Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.
Your capital engagement platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Capital Raising Tips
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
